Hiltonol

Generic Name: Hiltonol

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 59789-29-6

Unique Ingredient Identifier: 7KYP9TKT70

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Phase 1

Conditions: Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Melanoma (Skin)
Metastatic Cancer
Ovarian Cancer
Pancreatic Cancer

Interventions: Drug: cyclophosphamide
Drug: poly ICLC
Procedure: hepatic artery embolization
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2007-11-04

Last Posted Date: 2014-01-14

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 50

Registration Number: NCT00553683

Locations: 🇺🇸
Rutgrers University Hospital, Newark, New Jersey, United States

Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: poly ICLC
Drug: temozolomide
Radiation: radiation therapy

First Posted Date: 2005-12-07

Last Posted Date: 2019-06-12

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 97

Registration Number: NCT00262730

Locations: 🇺🇸
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 6 locations

Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: poly ICLC

First Posted Date: 2003-04-09

Last Posted Date: 2018-08-21

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 55

Registration Number: NCT00058123

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Terminated

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: poly ICLC

First Posted Date: 2003-01-27

Last Posted Date: 2018-07-18

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 31

Registration Number: NCT00052715

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy